Barry E. Greene - 13 Feb 2024 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role
President and CEO, Director
Signature
/s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Barry Greene
Issuer symbol
SAGE
Transactions as of
13 Feb 2024
Net transactions value
$0
Form type
4
Filing time
15 Feb 2024, 17:02:52 UTC
Previous filing
08 Aug 2023
Next filing
30 May 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SAGE Stock Option (Right to Buy) Award $0 +168,000 $0.000000 168,000 13 Feb 2024 Common Stock 168,000 $23.02 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities awarded on February 13, 2024 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 42,000 shares of common stock shall vest on the one year anniversary of February 13, 2024, with 126,000 shares vesting in 36 equal monthly installments thereafter.